ClinicalTrials.gg
Active, not recruitingNCT06162715GRABS-0Updated Nov 18, 2026

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

A Phase 2/3 interventional study of Tirzepatide and Standard of Care post-gastric bypass in Severe Obesity, Obesity and BMI Greater Than 30, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Vanderbilt University Medical Center · Phase 2/3, Interventional, and Treatment

How we know · 5 judgments · one reading being read again

Updated Nov 18, 2026Enrollment updatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Enrollment
80th of 150
33 · median 39
Started
2024
with 11 others
Phase 2/3
2 of 213
none open now
Primary completion
2026-10
later than 10 of 34 live
Registered
197th of 213
by date
Lead sponsor
5 of 213
Vanderbilt University Medical Center

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 80th largest by enrollment of the 150 interventional ones that give a count, is one of 12 that started in 2024, is one of 2 in phase 2/3, reaches primary completion later than 10 of the 34 other live ones, and was the 197th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who continue with the current standard of care for patients who have previously undergone Gastric Bypass Surgery.

Read the detailed description

Obesity affects nearly half of the U.S. population, impacting health outcomes including diabetes, cardiovascular risk, longevity, and quality of life. While bariatric surgery such as gastric bypass stands as the most effective intervention, 65% of individuals experience persistent obesity when undergoing surgical weight loss alone. Given the wide-ranging impact of obesity on health outcomes, a critical need exists to explore the efficacy of adjuvant weight loss therapies after gastric bypass surgery. Tirzepatide (TRZ), a type of glucagon-like peptide-1 receptor agonist, shows remarkable effectiveness in medical obesity with 25% weight loss after sustained therapy. However, nearly two-thirds of patients taking medications like TRZ have mild to moderate gastrointestinal (GI) symptoms, including nausea, vomiting, and abdominal pain. These medication side-effects could be a consequence of gastroparesis via vagal stimulation of the stomach, and may represent a major driver of weight loss. Limited data exist regarding use of these newer agents, such as TRZ, in patients who have undergone gastric bypass, which disrupts vagal nerves responsible for managing food transit and gastric emptying. This is a major and timely scientific gap in understanding whether gastric bypass surgery might mitigate these GI symptoms while allowing for enhanced weight loss with adjuvant TRZ use in the post-operative period. The investigators propose a pilot, phase II, open-label trial enrolling patients twelve months after gastric bypass with a nadir Body Mass Index ≥ 30 kg/m2. Study subjects will be randomized to either 24 weeks of TRZ or post-surgery standard of care. Subjects randomized to the standard of care arm will crossover to receive the intervention drug after 24 weeks of observation. Our proposal consists of two aims. First, the investigators will determine the impact of adjuvant TRZ administration on weight, total fat mass, and lean body mass in patients with a history of gastric bypass (Aim 1). Second, the investigators aim to investigate the frequency and severity of GI discomfort associated with TRZ utilizing a validated patient reported outcome questionnaire, and they will investigate the impact of TRZ on GI motility in patients with prior Gastric Bypass (Aim 2).

03

Conditions studied

  • Severe Obesity
  • Obesity
  • BMI Greater Than 30

Keywords

  • bariatric surgery
  • Roux-en-Y Gastric Bypass
  • GLP-1 Receptor Agonists
  • Tirzepatide
  • Obesity
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be able to understand and provide .
  2. ≥ 30 12 months after bariatric surgery.
  3. Age > 25 and \< 65
  4. Patients undergoing primary Roux-en-Y Gastric Bypass

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness of a subject to give written or comply with the study protocol.
  2. Diagnosis of type I Diabetes
  3. Revisional bariatric surgery (prior adjustable gastric band, sleeve gastric, vertical banded gastroplasty).
  4. Use of medications for type 2 diabetes treatment other than metformin
  5. > 8.5 in last 3 months.
  6. Patient-reported Tobacco, e-cigarette, or smoked marijuana use within 12 months As this would preclude patients from undergoing bariatric surgery.
  7. Personal history of pancreatitis as determined by history.
  8. Personal or family history of medullary thyroid cancer by history or multiple endocrine neoplasia syndrome type 2
  9. Pregnancy by urine testing, current lactation, or plans to become pregnant during the study period.
  10. Use of systemic in the past 28 days
  11. Myocardial infarction, unstable angina, stroke, or heart failure ( class II) within 1 year by history.
  12. History of solid organ transplant.
  13. History of physician-diagnosed (other than excised non-melanoma skin cancer) in the past 5 years.
  14. Current uncontrolled hypertension (systolic >150, diastolic >90) or untreated hyperthyroidism.
  15. Current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.
  16. Screening creatinine elevation with EGFR \< 60 at time of randomization.
  17. Tobacco use in last 12 months
  18. Pregnancy
  19. Prisoners
  20. Unable or unwilling to follow-up
  21. Unable to understand English/Spanish
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Tirzepatide Group

    Participants in the TRZ cohort will initiate a standardized dose titration as described in the package insert. Participants will begin TRZ at 2.5 mg for four weeks and then increase by 2.5 mg every 4 weeks to a maximum dose of 15 mg. If subjects experience intolerable GI symptoms, they will be allowed to decrease to a lower dose by 2.5 mg for 2 weeks, at which point another attempt at an increased dose will be trialed. Should patients not tolerate a higher dose a second time, they will have the dose again lowered by 2.5 mg and kept at the lower dose for the remainder of the study, except for patients who do not tolerate two attempts at 5 mg. For patients who fail to titrate to at least 5 mg TRZ, a third attempt at an increased dose will be attempted 4 weeks after the second decrease in dose. These patients will then remain on 5 mg for the remainder of the intervention period. All participants receiving TRZ will be pooled in terms of outcomes measures.

    Drug: Tirzepatide

  • Other
    Control - Standard of care Post-Gastric Bypass Surgery

    Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook for 24 weeks. After 24 weeks, particiapnts in the control arm will crossover to the Tirzepatide arm and receive 24 weeks of TRZ following the same titration.

    Other: Standard of Care post-gastric bypass

Interventions

  • Tirzepatide will be initiated 12 or 18 months (12 months + 24 weeks) after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 4 weeks following the recommended dose titration protocol. Patients will then complete a final 4 weeks of the study drug.

    Also known as: Zepbound, Mounjaro

  • OtherStandard of Care post-gastric bypass

    Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook. This includes recommendations for 64 oz of fluids per day, ≥60 grams of protein/day, and daily bariatric multivitamins. Patients will continue to have access to dedicated bariatric dietitians, advanced practice providers, and surgeons on an ad hoc basis per patients' request.

06

What researchers measure

Primary outcomes

  1. Weight loss

    Percent total weight change baseline to 24 weeks

    Time frame: baseline to 24 weeks

  2. Gastrointestinal symptoms

    Mixed-model adjusted mean difference at Week 24

    Time frame: baseline to 24 weeks

Secondary outcomes

  1. Change in body composition

    Changes in fat mass

    Time frame: baseline to 24 weeks

  2. Acetaminophen Area Under the Curve

    Changes in acetaminophen area under the curve in the intervention arm

    Time frame: baseline to 24 weeks

  3. Lean body mass

    Utilizing DXA, we will determine changes in lean body mass in both arms

    Time frame: baseline to 24 weeks

Other outcomes

  1. weight regain after TRZ discontinuation

    Degree of weight regain in intervention arm after discontinuation of TRZ

    Time frame: weeks 24 to 48

  2. Obesity remission

    incidence of obesity remission (BMI \< 30)

    Time frame: baseline to 24 weeks

  3. Remission of pre-existing comorbidities

    Incidence of remission of Type 2 Diabetes, Hyperlipidemia, Hypertension

    Time frame: baseline to 24 weeks.

  4. change in anthropometric measurements

    Changes in clinical obtained anthropometric measurements including waist circumference and waist-to-hip ratio

    Time frame: baseline to 24 weeks

  5. changes in body composition

    Changes in DXA-proven body composition including lean body mass and ratio of lean body mass to fat mass

    Time frame: baseline to 24 weeks.

  6. Change in PAGI-SYM sub-scale scores

    1\. heartburn/regurgitation, 2. nausea/vomiting, 3. postprandial fullness, 4. bloating, 5. upper and lower abdominal pain

    Time frame: baseline to 24 weeks

  7. change in PAGI-SYM scores in the TRZ arm

    Determining evolution of PAGI-SYM scores across treatment in both arms and after discontinuation of TRZ in the intervetion arm.

    Time frame: baseline to week 24 and week 24 to week 28 (after TRZ discontinuation)

  8. Difference in acetaminophen AUC between groups

    difference in acetaminophen AUC between Intervention and control groups

    Time frame: baseline to 24 weeks

  9. Changes in response to mixed meal tolerance test

    change in intervention arm mixed meal AUC for Glucose, Insulin, and GLP-1

    Time frame: baseline to 24 weeks

  10. Medication adherence

    Incidence of missed doses, patient-driven drug discontinuation, patient withdrawal in intervention arm

    Time frame: baseline to 24 weeks

  11. Adverse events and healthcare resource utilization

    Incidence of adverse events including emergency department visits, hospitalizations, and reoperations

    Time frame: baseline to 48 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Samuels JM, Williams CR, Patel MB, Self WH, Funk LM, Roumie C, Spann MD, Northup CJ, Ye F, Irlmeier R, Sohn I, Zhu Y, Niswender K. GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics. Diabetes Obes Metab. 2026 Sep 8. doi: 10.1111/dom.71320. Online ahead of print. PubMed 42712125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All participant-level data will be preserved and shared. Shared data will be deidentified prior to sharing. Clinicaltrials.gov will document recruitment progress and final results. Study protocols will be shared with publications as supplementary data and made available upon request. All participant consent document will be collected and stored electronically utilizing the REDCap study data repository. The REDCap data warehouse will also contain the study data dictionary. Study protocols have also been published on the ClinicalTrials.gov and any protocol amendments will be reflected on the ClinicalTrials.gov study page. The investigators will utilize the Research Electronic Data Capture (REDCap) data warehouse maintained locally at Vanderbilt for all data collection. Upon study completion and prior to closing the REDCap data warehouse for this study, the investigators will archive all data after removing patient identifiers in the Open Science Framework data repository.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Per institutional policy, data will be maintained in the local REDCap data repository for 6 years after closure of the study. Following this period, data will be deidentified and uploaded to the OSF repository, which has funding for at least 50 years of data storage.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Oct 2026, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2027 → Oct 2026 and completion Dec 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2023
First posted
Dec 8, 2023
StartActual
Oct 30, 2024
Primary completionActual
Oct 10, 2026was Jan 2027
CompletionEst.
Apr 30, 2027was Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 1, 2027→Oct 10, 2026 (actual)
Nov 10, 2026
Study completion
Dec 1, 2027→Apr 30, 2027
Nov 10, 2026
Enrollment
30 (estimated)→33 (actual)
Nov 18, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedBMI >≥ 30 12 months after bariatric surgery.
Exclusion criteria
  • EditedUse of medications for type 2 didiabetes treatment other than metformin
Nov 10, 2026
Primary outcomes
2 description edited
What changed in the outcomes
  • DescriptionGastrointestinal symptoms: how it is measured was reworded
  • DescriptionWeight loss: how it is measured was reworded
Nov 10, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42712125 ↗
Nov 10, 2026
Show all 2 updates
  1. Nov 18, 2026
    Enrollment 30 (estimated)→33 (actual)
    + 1 other change: arm descriptions
  2. Nov 10, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42712125 ↗
    Primary completion Jan 1, 2027→Oct 10, 2026 (now actual)
    Study completion Dec 1, 2027→Apr 30, 2027
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedBMI >≥ 30 12 months after bariatric surgery.
    Exclusion criteria
    • EditedUse of medications for type 2 didiabetes treatment other than metformin
    Primary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionGastrointestinal symptoms: how it is measured was reworded
    • DescriptionWeight loss: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06162715
Responsible party
Jason Samuels (Assistant Professor of Surgery, Vanderbilt University Medical Center) — Principal investigator
First posted
Dec 8, 2023
Start date
Oct 30, 2024
Primary completion
Oct 10, 2026
Completion
Apr 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jason M Samuels, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion